In the Forget P et al. 2014 study, the researchers conducted a retrospective study on "the effect of a single intraoperative dose of ketorolac or diclofenac, and the preoperative neutrophil:lymphocyte ratio during conservative primary breast cancer surgery, on disease-free survival".
Findings: The single intraoperative use of NSAIDS (ketorolac and diclofenac) improved the disease free survival, along with improved overall survival. Those breast cancer patients having a neutrophil:lymphocyte ratio over 3.3 had a shorter disease free survival.
Conclusion for Lumpectomy Surgery: "Intraoperative NSAIDs and higher preoperative neutrophil:lymphocyte ratio are associated with improved outcome in conservative breast cancer surgery."
(See Forget P et al., Intraoperative Use of Ketorolac or Diclofenac is Associated with Improved Disease-Free Survival and Overall Survival in Conservative Breast Cancer Surgery, Br J Anesth, 2014.)